Breyer Capital Names Head of Healthcare and Life Sciences

Breyer Capital, a premier global investment firm focused on backing high-impact entrepreneurs, today announced that Morgan Cheatham has joined the firm as a Partner and Head of Healthcare and Life Sciences. In this new role, Cheatham will lead Breyer Capital’s efforts in early-stage healthcare and life sciences investing – spearheading the firm’s practice and focusing on breakthrough biomedical technologies and innovative models of care. He will partner closely with founder Jim Breyer and the firm’s healthcare and life sciences portfolio companies, including OpenEvidence, Artera, Arena Bioworks, Atropos Health, Cleerly, Iterative Health, Slope, and SandboxAQ.

Cheatham joins Breyer Capital from Bessemer Venture Partners, where he was a Vice President focused on healthcare and life sciences investments across software, services, therapeutics, and diagnostics, and spearheaded the firm’s thesis in healthcare AI. Cheatham sourced more than a dozen early-stage investments, including Abridge and Hinge Health — both of which have grown into multi-billion-dollar, category-defining companies — as well as rapidly scaling companies such as Plenful and Turquoise Health. During his tenure, he helped incubate and launch a cardiology business and served as Interim CEO at a fast-growing telemedicine company. Cheatham played an integral role in Bessemer’s biotech practice, partnering with companies like Seismic Therapeutics, and co-founding Decoding Bio, a digital platform focused on the future of AI and biotech. In addition to his track record of sourcing and supporting high-potential companies, Morgan was named to Forbes’ 30 Under 30 list for Venture Capital in 2023. A physician by training, Cheatham will continue to serve on the Editorial Team at NEJM AI and as a Clinical Fellow in Genomics at Harvard.

“We are thrilled to welcome Morgan to Breyer Capital,” said Jim Breyer. “He brings a strong track record in healthcare and life sciences investing, deep sector expertise, and a powerful network of innovators. Morgan shares our passion for advancing technologies that improve lives – whether through breakthroughs in biomedical science or through new models of care that transform how patients access and experience healthcare. We’re excited about the impact he’ll have on our portfolio and the broader healthcare ecosystem.”

“Scientific and technological progress is outpacing the evolution of healthcare delivery,” said Cheatham. “The next generation of healthcare and life sciences will emerge from the convergence of breakthrough discoveries, urgent clinical needs, and meaningful institutional change. I look forward to building on Breyer Capital’s strong track record of supporting visionary founders at this intersection, and to invest in teams that are reimagining healthcare to address the most pressing challenges of our time.”

About Breyer Capital

Breyer Capital is a premier global venture capital and private equity investor focused on catalyzing high-impact entrepreneurs. Founded by legendary investor Jim Breyer in 2006, Breyer Capital makes long-term, idea-driven strategic investments in artificial intelligence, healthcare, life sciences, enterprise, consumer, and financial technologies. The firm prides itself on maintaining an openness to experimentation that can lead to long-term breakthrough performance and partnering with founders and teams who are passionate about building transformative companies anchored in technology. For more information, please visit www.breyercapital.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250424391812/en/